Reports Q4 revenue $74.71M, consensus $63.81M. “Our team is delivering operational momentum in the business. As previously announced in January, in Europe we are showing early signs of progress, particularly in Spain and the U.K.; our U.S. business is continuing its IPE market leadership; and our Rest of World partners are advancing plans to maximize patient uptake,” said Patrick Holt, President & CEO of Amarin. “We have initiated the shareholder approval process to execute up to a $50 million share repurchase program. Our focus remains on building momentum in 2024 and beyond for Amarin.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRN:
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Options Volatility and Implied Earnings Moves Today, February 29, 2024
- Amarin Corporation Plc (AMRN) Q4 Earnings Cheat Sheet
- Largest borrow rate increases among liquid names
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
